Eli Lilly and Co (NYSE:LLY) insider Donald A. Zakrowski sold 876 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $77.55, for a total value of $67,933.80. Following the completion of the sale, the insider now owns 4,130 shares of the company’s stock, valued at $320,281.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eli Lilly and Co (NYSE:LLY) traded up $1.56 during mid-day trading on Friday, hitting $78.75. 4,771,177 shares of the stock were exchanged, compared to its average volume of 5,314,162. The company has a market cap of $86,710.00, a PE ratio of 48.61, a PEG ratio of 1.45 and a beta of 0.23. The company has a quick ratio of 1.03, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a one year low of $73.69 and a one year high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.95 EPS. research analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is 138.89%.
A number of analysts recently weighed in on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group reiterated a “hold” rating and set a $80.00 price target on shares of Eli Lilly and in a report on Friday, February 2nd. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Jefferies Group set a $100.00 price target on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Bank of America decreased their price target on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $93.22.
Several hedge funds have recently added to or reduced their stakes in LLY. Avestar Capital LLC bought a new position in shares of Eli Lilly and during the 4th quarter worth about $100,000. Gradient Investments LLC bought a new position in shares of Eli Lilly and during the 4th quarter worth about $103,000. Acrospire Investment Management LLC boosted its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the 2nd quarter worth about $128,000. Finally, San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and during the 2nd quarter worth about $129,000. 75.71% of the stock is currently owned by institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.